Q-omics provides the consensus-scored HOXB-AS3 profile across patient tissues and cancer cell-line models. HOXB-AS3 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, HOXB-AS3 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, HOXB-AS3 RNA expression shows 14,959 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRP, and KIRC as cancer lineages where HOXB-AS3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HOXB-AS3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HOXB-AS3 survival associations across molecular data types. HOXB-AS3 RNA expression shows survival associations in the most cancer types (28). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HOXB-AS3 RNA expression–survival associations across cancer types. High HOXB-AS3 expression shows unfavorable associations in KIRP, KIRC, ACC and LGG, but favorable associations in BLCA and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for HOXB-AS3 RNA expression.
This table summarizes HOXB-AS3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HOXB-AS3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HOXB-AS3 shows lower tumor expression in KIRC, KIRP, LUSC and LUAD and higher tumor expression in HNSC and BLCA. The KIRC box plot shows higher HOXB-AS3 RNA expression in normal versus tumor tissue (log2 FC = −3.103, t-test p < 0.001).
This table shows molecular features associated with HOXB-AS3 in patient tissues and cancer cell lines. In patient samples, HOXB-AS3 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, HOXB-AS3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in CNS.
